MIRAMAR, Fla., Oct. 07, 2020 (GLOBE NEWSWIRE) -- G
Post# of 36568
(Total Views: 326)
Posted On: 10/07/2020 3:46:01 PM
MIRAMAR, Fla., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for tomorrow’s investor conference call on Thursday October 8, 2020 at 8:00 AM Eastern time.
The access information for the investor conference call is as follows:
Domestic US/Canada – 1-877-830-2587
Direct Toll / International - 1-785-424-1734
Program Title: NuGenerex Immuno-Oncology - Investor Conference Call
Conference ID – 30417
Agenda
Signed licensing and distribution agreement with Bintai Kinden for the development of Ii-Key-SARS-CoV-2 vaccine against COVID-19
COVID-19 Vaccine Scientific and Clinical Advisory Board
Status of COVID-19 Vaccine international initiatives
NuGenerex Immuno-Oncology Listing Plans
On the call, Generex President & Chief Executive Officer, Joseph Moscato and his team will provide an overview of NuGenerex Immuno-Oncology and the company’s development efforts for a COVID-19 vaccine using the Ii-key technology to create a “Complete Vaccine” that activates a targeted, neutralizing antibody response and a cellular response that can provide the long term immune memory that is essential to stopping this devastating pandemic.
Mr. Moscato said, “I look forward to speaking with our shareholders to discuss the listing of NuGenerex Immuno-Oncology on a national exchange and our plans to expand the Ii-Key technology platform to generate new immunotherapies and vaccines. We have a number of exciting initiatives that I am eager to present, and our closing of the Bintai Kinden licensing and distribution agreement for our COVID-19 Complete Vaccine. We are excited that we now have the money to advance our Ii-Key vaccine through the clinical and regulatory process, and as always, we welcome questions from shareholders during the call.”
The access information for the investor conference call is as follows:
Domestic US/Canada – 1-877-830-2587
Direct Toll / International - 1-785-424-1734
Program Title: NuGenerex Immuno-Oncology - Investor Conference Call
Conference ID – 30417
Agenda
Signed licensing and distribution agreement with Bintai Kinden for the development of Ii-Key-SARS-CoV-2 vaccine against COVID-19
COVID-19 Vaccine Scientific and Clinical Advisory Board
Status of COVID-19 Vaccine international initiatives
NuGenerex Immuno-Oncology Listing Plans
On the call, Generex President & Chief Executive Officer, Joseph Moscato and his team will provide an overview of NuGenerex Immuno-Oncology and the company’s development efforts for a COVID-19 vaccine using the Ii-key technology to create a “Complete Vaccine” that activates a targeted, neutralizing antibody response and a cellular response that can provide the long term immune memory that is essential to stopping this devastating pandemic.
Mr. Moscato said, “I look forward to speaking with our shareholders to discuss the listing of NuGenerex Immuno-Oncology on a national exchange and our plans to expand the Ii-Key technology platform to generate new immunotherapies and vaccines. We have a number of exciting initiatives that I am eager to present, and our closing of the Bintai Kinden licensing and distribution agreement for our COVID-19 Complete Vaccine. We are excited that we now have the money to advance our Ii-Key vaccine through the clinical and regulatory process, and as always, we welcome questions from shareholders during the call.”
(3)
(0)